ストックスクリーナーアプリを入手
31.46
0.25%
-0.08
Pharvaris Nv (PHVS) 最新ニュース
PHVS Technical Analysis & Stock Price Forecast - Intellectia AI
Pharvaris (PHVS) CMO reports 109 shares withheld for RSU tax obligations - Stock Titan
Single capsule rapidly eased most HAE attacks in Pharvaris study - Stock Titan
Pharvaris N.V. (PHVS) Presents at World Orphan Drug Congress (WODC) USA 2026Slideshow - Seeking Alpha
Pharvaris (PHVS) Shows Modest Gains After Recent Pullback, Testing Key ResistanceSystematic Flow - newsline.com
Does Pharvaris (PHVS) have the potential to rally 59.93% as Wall Street analysts expect? - MSN
Pharvaris Sets June 26, 2026 AGM as Late-Stage Angioedema Programs Advance - TipRanks
Pharvaris (Nasdaq: PHVS) details AGM plans and NDA timeline for HAE therapy - Stock Titan
Shareholders of Pharvaris to vote at June 26 annual meeting - Stock Titan
Why Pharvaris (PHVS) Is Up 8.6% After Expanding Deucrictibant HAE Data And Regulatory Plans - Sahm
Pharvaris N.V. (PHVS) Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Progress in HAE Pipeline - newsline.com
Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000 - AOL.com
Insider Sell: Anna Nijdam Sells Shares of Pharvaris NV (PHVS) - GuruFocus
Pharvaris (PHVS) accounting officer sells 2,670 common shares on market - Stock Titan
A Look At Pharvaris (PHVS) Valuation As Deucrictibant Data Advances Toward Key EAACI 2026 Catalyst - Sahm
Understanding Momentum Shifts in (PHVS) - Stock Traders Daily
Anna Nijdam reports sales of PHVS common shares (PHVS) - Stock Titan
PHVS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Pharvaris N.V. (PHVS) Presents at The 2026 Eastern Allergy ConferenceSlideshow (NASDAQ:PHVS) 2026-05-30 - Seeking Alpha
Pharvaris (PHVS) Holds Near Resistance as Shares Edge Higher on Modest VolumeRetail Driven Moves - The Legal Advocate
Pharvaris Trades Flat as Investors Wait for June Data Update - Bez Kabli
Pharvaris (PHVS) Edges Higher Amid Tight Trading Range, Testing Resistance at $31.61Death Cross - The Legal Advocate
Hereditary angioedema oral drug data headed to European allergy congress - Stock Titan
Pharvaris (PHVS) director Monges sells 9,667 shares, updates ownership - Stock Titan
Pharvaris (PHVS) accounting officer exercises options, sells 7,330 shares - Stock Titan
Pharvaris (PHVS) CFO/CLO Nassif sells 10,000 shares, corrects ownership - Stock Titan
Oppenheimer maintains Pharvaris NV (PHVS) outperform recommendation - MSN
Avoiding Lag: Real-Time Signals in (PHVS) Movement - Stock Traders Daily
B of A Securities Upgrades Pharvaris N.V. (PHVS) - MSN
Anna Nijdam proposes sale of 5,501 PHVS shares via Morgan Stanley (PHVS) - Stock Titan
Pharvaris (PHVS) director sells 10,000 shares, exercises options under 10b5-1 - Stock Titan
Pharvaris (PHVS) CEO Berndt Modig updates direct and indirect share holdings - Stock Titan
[144] Pharvaris N.V. SEC Filing - Stock Titan
Pharvaris (PHVS) CEO Modig sells 2,292 shares under Rule 10b5-1 plan - Stock Titan
PHVS (NASDAQ) Form 144/A: brokered resale of 4,667 and 5,333 common shares - Stock Titan
Director Robert Glassman of Pharvaris (PHVS) sells 10,000 shares after exercising options - Stock Titan
Pharvaris (PHVS) technical ops chief sells 8,748 shares in open market - Stock Titan
Pharvaris (PHVS) CCO Souverijns sells 10,000 shares under Rule 10b5-1 plan - Stock Titan
Pharvaris N.V. (PHVS) Fell -5.23% — Is a Recovery Ahead? 2026-05-18{涓偂鍓爣棰榼 - Newser
Pharvaris N.V. (PHVS) Delivers Q1 2026 Beat — EPS $-0.59 vs $-0.73 ExpectedShare Dilution Risk - Newser
The Bull Case For Pharvaris (PHVS) Could Change Following Major Equity Raise And NDA ProgressLearn Why - simplywall.st
Viking Global affiliates hold 3.65M shares of Pharvaris (PHVS) after amendment - Stock Titan
PHVS (NASDAQ: PHVS) reports 10b5-1 sales of 23,333; 2,292 RSUs - Stock Titan
Affiliate files notice to sell 4,667 & 4,137 shares (NASDAQ: PHVS) - Stock Titan
Pharvaris N.V. (PHVS) Q4 2025 Earnings Miss: EPS $-0.72 vs $-0.63 ExpectedEarnings Surprise Report - Newser
Discipline and Rules-Based Execution in PHVS Response - Stock Traders Daily
Why Pharvaris Shares Are Suddenly Sliding Today - TipRanks
Pharvaris Equity Raise Supports Late Stage HAE Push And Valuation Case - Yahoo Finance
Pharvaris (PHVS) CMO reports 226 shares withheld for RSU taxes - Stock Titan
Pharvaris N.V. Stock 12‑Month Price Target Cut to $46.57, Implies 49% Upside - TradingView
Pharvaris N.V. Stock 12‑Month Price Target Cut to $46.51, Implies 49% Upside - TradingView
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):